Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia

• Published in: Antimicrobial agents and chemotherapy Vol. 60; no. 9; pp. 5276 - 5284
• Main Authors: Baxi, Sanjiv M., Clemenzi-Allen, Angelo, Gahbauer, Alice, Deck, Daniel, Imp, Brandon, Vittinghoff, Eric, Chambers, Henry F., Doernberg, Sarah
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 01.09.2016
• Subjects: Adult; Aged; Anti-Bacterial Agents; Anti-Bacterial Agents - therapeutic use; Bacteremia; Bacteremia - diagnosis; Bacteremia - drug therapy; Bacteremia - microbiology; Bacteremia - mortality; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Patient Readmission; Prognosis; Proportional Hazards Models; Prospective Studies; Severity of Illness Index; Staphylococcal Infections; Staphylococcal Infections - diagnosis; Staphylococcal Infections - drug therapy; Staphylococcal Infections - microbiology; Staphylococcal Infections - mortality; Staphylococcus aureus; Staphylococcus aureus - drug effects; Staphylococcus aureus - growth & development; Staphylococcus aureus - pathogenicity; Susceptibility; Treatment Outcome; Vancomycin; Vancomycin - therapeutic use; Vancomycin Resistance

Staphylococcus aureus bacteremia (SAB) is a tremendous health burden. Previous studies examining the association of vancomycin MIC and outcomes in patients with SAB have been inconclusive. This study evaluated the association between vancomycin MICs and 30- or 90-day mortality in individuals with SA...